This case focuses on the development of AZT, the first drug approved for the treatment of AIDS, and the problems faced by its British producer, Wellcome PLC, as it decides how the drug price. The case contains a brief overview of the disease itself, drugs in development to be able to treat the pharmaceutical industry and its practices, and the history of the Wellcome PLC and its U.S. subsidiary, Burroughs Wellcome. The case A closes with analysts’ forecasts for the soon-to-be-announced price of AZT … Read more »

This case focuses on the development of AZT, the first drug approved for the treatment of AIDS, and the problems faced by its British producer, Wellcome PLC, as it decides how the drug price. The case contains a brief overview of the disease itself, drugs in development to be able to treat the pharmaceutical industry and its practices, and the history of the Wellcome PLC and its U.S. subsidiary, Burroughs Wellcome. The case A closes with analysts’ forecasts for the soon-to-be-announced price of AZT. See also the case B, and C is the case.
«Hide

from
Jeanne M. Liedtka
Source: Darden School of Business
9 sides.
Publication Date: Apr 15, 1991. Prod #: UV0237-PDF-ENG
Burroughs Wellcome and the Pricing of AZT (A) HBR case solution

[related_post themes="flat"]